Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bellus Health Inc (NQ: BLU )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bellus Health Inc

< Previous 1 2 Next >
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
BELLUS Health: Q1 Earnings Insights
Via Benzinga
GSK Stock: A Value Trap or a Hidden Gem?
GSK, formerly known as GlaxoSmithKline, is struggling after a complicated earnings season. Here's why GSK stock is still a buy. 
Via InvestorPlace
Where BELLUS Health Stands With Analysts
Via Benzinga
3 Biotechs That Might Get Bought Out in 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
Was This Acquisition a Savvy Play by This Big Pharma Stock?
The British drugmaker picked up a potential blockbuster drug in its deal for Bellus Health. 
Via The Motley Fool
Second Quarter Outlook For Biotech Stocks
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
Why This Nasdaq Stock Caught Fire This Week
A wave of bargain buying benefited the gene therapy company's shares this week. 
Via The Motley Fool
Why Shares of Bellus Health Skyrocketed This Week
The company has received a buyout offer from GSK. 
Via The Motley Fool
Dow Edges Higher; Goldman Sachs Posts Upbeat Earnings
U.S. stocks traded mixed toward the end of trading, with the Dow Jones turning higher on Tuesday. The Dow traded up 0.04% to 34,000.96 while the NASDAQ fell 0.13% to 12,141.79. The S&P 500, also rose,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
Via Benzinga
Dow Dips Over 100 Points; Bank of America Earnings Beat Estimates
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 100 points on Tuesday. The Dow traded down 0.42% to 33,842.93 while the NASDAQ fell 0.10% to 12,146.16. The S&P 500,... 
Via Benzinga
Why BELLUS Health Stock Is Rocketing Higher Today
A $2 billion buyout agreement with GSK is lighting a fire under the biotech's stock today. 
Via The Motley Fool
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional... 
Via Benzinga
US Stocks Mixed; Housing Starts Edge Lower In March
U.S. stocks traded mixed this morning, with the Nasdaq Composite dropping over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.12% to 33,945.01 while the NASDAQ rose... 
Via Benzinga
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal
Shares of its takeover candidate nearly doubled on the news. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
Via Benzinga
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories
Benzinga Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs 
Via Benzinga
Why Is Gamida Cell (GMDA) Stock Up 48% Today?
Gamida Cell (GMDA) stock is taking off on Tuesday after getting an update from the FDA concerning cell therapy Omisirge. 
Via InvestorPlace
Why Is ContraFect (CFRX) Stock Down 14% Today?
ContraFect (CFRX) stock is dropping on Tuesday after the company revealed a notice from the Nasdaq Exchange and undergoing a rally yesterday. 
Via InvestorPlace
Why Is Bellus Health (BLU) Stock Up 98% Today?
Bellus Health (BLU) stock is taking off on Tuesday after the company announced a $2 billion acquisition deal with GSK (GSK). 
Via InvestorPlace
Why Digital Brands Group Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving Premarket
Gainers Super League Gaming, Inc. (NASDAQ: SLGG) jumped 119.8% to $0.9408 in pre-market trading. LandVault and Super League disclosed a strategic partnership to provide brands with scalable solutions... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a look at the biggest pre-market stock movers traders will want to keep an eye on Tuesday! 
Via InvestorPlace
BELLUS Health, Sunrun And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
GSK To Strengthen Specialty Medicines and Respiratory Pipeline With $2B BELLUS Health Acquisition
Via Benzinga
Expert Ratings for BELLUS Health
Over the past 3 months, 4 analysts have published their opinion on BELLUS Health (NASDAQ:BLU) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Here's Why BELLUS Health Shares Are Diving Lower Today
BELLUS Health Inc (NASDAQ: BLU) shares are trading lower by 10.80% to $9.00 Thursday morning after the company priced an offering of 16,540,541 shares at a price of $9.25 per share. 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
U.S. Stock Futures Down Ahead Of Bank Earnings, Producer Price Index
Pre-open movers 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.